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Background. Exercise is emerging as an important aspect in the management of disease-
related symptoms and functional decline in people with Huntington disease (HD). Long-term 
evaluation of physical activity and exercise participation in HD has yet to be undertaken. 
Objective. The objective is to investigate the feasibility of a nested randomized controlled 
trial (RCT) alongside a longitudinal observational study of physical activity and exercise 
outcomes in people with HD.  
Design. This will be a 12-month longitudinal observational study (n = 120) with a nested 
evaluation of a physical activity intervention (n = 30) compared to usual activity (n = 30) 
using a “Trial within a Cohort” (TWiC) design. 
Setting: The study will take place in HD specialist clinics in Germany, Spain, and the USA, 
with intervention delivery in community settings.  
Participants. The participants will be those with early-mid stage HD participating in the 
‘Enroll-HD’ study.  
Intervention. This will be a 12-month physical activity behavioral change intervention, 
delivered by physical therapists in 18 sessions, targeting uptake of aerobic exercise and 
increased physical activity.   
Measurements. All participants (n = 120) will complete Enroll-HD assessments (motor, 
cognitive, behavioral, and quality of life) at baseline and 12 months. Additional Physical 
ACtivity and Exercise Outcomes in Huntington Disease (PACE-HD) assessments include 
fitness (predicted VO2
 
max), self-reported and quantitative measures of physical activity, 
disease-specific symptoms, and walking endurance. RCT participants (n = 60) will complete 
an additional battery of quantitative motor assessments and a 6-month interim assessment. 
Enroll-HD data will be linked to PACE-HD physical activity and fitness data.  
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Limitations. The limitations include that the embedded RCT is open, and assessors at RCT 
sites are not blinded to participant allocation. 
Conclusion. PACE-HD will enable determination of the feasibility of long-term physical 
activity interventions in people with HD.  The novel TWiC design and incorporation of data 
linkage has potential to reduce participant burden. This design could be applied to other 
neurological diseases and movement disorders where recruitment and retention are 
challenging.  
 
[H2]Background and Rationale 
Huntington Disease (HD) is an inherited neurodegenerative disease resulting in the loss of 
striatal neurons leading to disruption of cortico-striatal pathways.  HD is characterised by 
progressive deficits in cognition, behaviour and movement
1
 leading to decline in function,  
performance of living daily activities and quality of life,
2
 with associated caregiver and 
socioeconomic burdens.
3,4
 There is evidence that modifiable lifestyle factors such as 
education, activity levels and specific motor training may minimize the functional impact of 
the disease and targeting motor impairments may play a role in delaying disease 
progression.
5,6
  
Clinical studies of short-term exercise interventions have demonstrated improvements 
in fitness,  motor impairment and quality of life in people with HD.
7–12
  Longer term 
pragmatic evaluations of well-defined exercise interventions are required, although such 
studies are challenging to set up and deliver, particularly in rare diseases.  Such studies are 
limited by poor recruitment, retention and generalizability.  Embedded studies, or trials 
within cohorts (TWiCs),
13
 provide an efficient method for recruitment, and may reduce 
burden through the use of routinely collected prospective outcome data. Generalizability can 
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be better achieved through access to cohort natural history data, information on routine care 
as well as relevant lifestyle factors.  TWiC designs are most suited to open trials and 
comparisons to treatment as usual, which may introduce elements of assessor bias. The 
inclusion of measures less subject to investigator bias, including wearable technologies for 
the assessment of physical activity and utilizing quantitative motor and cognitive 
assessments, is therefore crucial. 
[H2]Trial Design 
PACE-HD uses a TWiC design,
13
 where we are conducting a 12-month, observational cohort 
study in people with early and mid-stage HD (n = 120) with a nested randomised controlled 
trial (RCT) of a 12 month physical activity intervention (n = 30) compared to the pragmatic 
choice of activity as usual (n = 30) (Fig. 1). The intervention will be delivered by physical 
therapists, targeting uptake of aerobic exercise and increased physical activity.   PACE-HD 
will utilise Enroll-HD,
14
 a global clinical research platform designed to facilitate clinical 
research in Huntington’s disease. Core data sets are collected annually on all research 
participants as part of this multi-centre longitudinal observational study of HD. Data are 
monitored for quality and accuracy using a risk-based monitoring approach. All sites are 
required to obtain and maintain local ethics committee approvals. Researchers can apply for 
access to anonymised Enroll-HD data via a specific data request
15
 subject to approval from 
the Enroll-HD Scientific Review Committee. PACE-HD study data will be supplemented by 
linking data from participant’s annual Enroll-HD assessments.  At the conclusion of the study 
the fully integrated data set will be shared with Enroll-HD and made available to other 
researchers. 
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[H2]Study Objectives and Outcomes 
The primary objective of this study is to establish the feasibility of a within-cohort nested 
RCT of a 12-month physical activity intervention in people with HD. The primary outcome is 
feasibility of the nested RCT in terms of recruitment, retention, data completeness, 
adherence, fidelity and acceptability. Secondary objectives include: (1) exploration of effect 
estimates for long-term exercise in HD compared to usual activity, (2) exploration of the 
influence of physical activity and function on cognitive, motor and functional abilities over a 
one-year period, and (3) exploration of the predictive validity of physical fitness at 6 months 
on motor and cognitive outcomes.  
[H1]METHODS 
[H2]Study Population 
Participants (n = 120) will be recruited at six sites.  Three sites will serve as observational 
sites only, and three additional sites will conduct the nested RCT (see supplementary 
information for full sites details). Sites have been selected as currently recruiting Enroll-HD 
centres with capability and potential participant capacity required to deliver the study as 
intended.  Potentially eligible participants will be identified according to study inclusion 
criteria from local Enroll-HD records.  Inclusion criteria are: (1) confirmed genetic diagnosis 
of HD, (2) over 18 years of age, (3) currently registered as a participant in Enroll-HD, and (4) 
up to and including stage 2 disease status (defined as having a total functional capacity of 7-
13). Exclusion criteria are:  (1) diagnosis of juvenile onset HD, (2) history of co-morbid 
neurological conditions such as multiple sclerosis or stroke, (3) an acute orthopaedic 
condition, eg, a sprained ankle of fracture, and (4) inability or unwillingness to give written 
informed consent.  Interested participants will be provided with written information about the 
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study and invited to attend a baseline assessment.  Written informed consent will be obtained 
by appropriately trained and delegated site staff.  
[H2]Sample Size 
As the primary outcome of PACE-HD is feasibility of the nested RCT (in terms of 
recruitment, retention, data completeness, safety, fidelity and acceptability) a formal sample 
size calculation for efficacy has not been performed and formal hypothesis testing will not be 
carried out. Effect sizes and 95% confidence intervals will be presented to inform planning of 
future studies.   For a total sample size of 120 participants recruited into the study we can 
determine a 95% confidence interval for a 70% retention rate to within ± 8.2%.  
[H2]Assessments and Secondary Outcome Measures 
All study participants will complete the extended battery of ‘Enroll-HD’ assessments 
(eAppendix A)
16
 at baseline and 12 months at the participating site (typically hospital or 
rehabilitation centre). Participants in the nested RCT will complete an additional battery of 
novel, quantitative motor assessments (Clinch Token Transfer Test (C3T),
17
 Geneactiv 
accelerometers
18
 for physical activity monitoring and Q-Motor and Q-Cog assessments),
19
 as 
well as a 6-month interim assessment (Table). Both baseline and 12-month assessments must 
be conducted within +/- 6 weeks of the participant’s annual Enroll-HD visit.   
[H2]Randomization and Blinding 
At RCT sites, on completion of baseline assessments, participants will be randomly assigned 
1:1 to receive the 12-month activity intervention or activity as usual. Randomisation will be 
performed via the web-based study database using a minimization technique to maintain 
allocation concealment.  The randomization allows for balancing by age (above or below 50 
years of age), gender and motor impairment (above or below a Unified Huntington’s Disease 
Rating score (UHDRS) [total motor score] of 40) at baseline and stratified by country. For 
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pragmatic reasons (including the nature of the intervention) neither participants nor assessors 
will be blind to allocation.  
[H2]Physical Activity Intervention  
The PACE-HD intervention is a physical activity behavioural change intervention based on 
knowledge developed in two previous studies:  Exert-HD
9
 and Engage-HD.
20
  The 
intervention will be delivered by trained, licensed physical therapists focusing on promoting 
strategies to engage in aerobic exercise and physical activity (Fig. 2).   The program uses a 
disease-specific workbook and participant-coach interaction that emphasizes relatedness, and 
promotes participant autonomy and competence.
21
 The intervention framework is 
underpinned by self-determination theory
22
 a fundamental component of which is 
collaborative regulation that specifically considers social–contextual-disease specific 
conditions. This emphasizes the importance of working in a collaborative way with 
participants, as well as understanding the progressive nature of HD and the changing needs of 
the participant so that aspects such as access to healthcare and fitness facilities, social 
situation and adaptation to a participant’s ongoing cognitive and behavioural status are all 
taken into account during intervention delivery. 
 The program will consist of 18 face-to-face, 1:1 physical therapy sessions over 12 
months. The timing and location (at participant’s home or rehabilitation facilities at site) of 
these sessions will be determined by the participant in consultation with their therapist. The 
suggested timing of interventions sessions are three sessions in month one and two, two 
sessions in months three and six and monthly sessions in months four, five and 7 to 12. A 
therapist manual will be used to provide a structured approach to sessions, focusing on 
exercise uptake (specifically aerobic and strengthening exercises) and engagement in regular 
physical activity. In partnership with the therapist, participants will develop activity goals that 
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will be monitored and adjusted throughout. The therapist will work with the participant, using 
the agreed activity goals as a focus to tailor their exercise program to build up to regular 30 
minute periods of exercise 3 to 5 times per week and strengthening exercises 2 to 3 times per 
week. Participants will be asked to keep monthly physical activity diaries (in paper format or 
directly entered into the study database) to record the amount and type of physical activity 
undertaken. Participants will be given the option to use wearable activity monitors (Fitbit 
Charge 2) to be used throughout the 12-month period as a means to facilitate/monitor activity 
and sedentary behaviours. We anticipate that some participants will choose not to use a FitBit 
and so the activity diaries will form the principal method of monitoring exercise. We are not 
using the FitBit devices as an outcome assessment, but measures elicited from FitBit use will 
be explored as part of the overall feasibility assessment. Therapists will send regular 
reminders for attending upcoming appointments, completing exercise diaries and uploading 
of FitBit data via app-syncing. Preferred communication methods will be discussed at the 
first session, and can be by phone, e-mail or text messaging.  
People with HD need flexibility in terms of access to exercise facilities,
23
 and this is 
critical to successful adherence to exercise in this population. Therefore, each participant will 
be provided with a choice of exercise equipment options to be used for independent sessions 
in the home, or participants can choose to exercise in a gym setting.  
  Participants allocated to activity as usual will not receive the physical activity 
intervention and will be asked to continue with their usual level of physical activity for the 12 
month follow-up period. When participants are randomized to activity as usual they will be 
referred to the Huntington’s Disease Society of America web pages for advice on healthy 
eating (http://hdsa.org/living-with-hd/nutrition). They will not receive visits but will be asked 
to record their activity in monthly diaries. These participants will also receive monthly 
prompts via their preferred method of communication to remind them to complete and return 
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the diaries to their local site. The intervention is fully described in the Template for 
Intervention Description and Replication (TiDiER)
24
 format (eAppendix B). 
 
[H2]Data Collection, Management, and Linkage 
All participants will be assigned a unique participant identification number (PID), which is 
used to identify all data relating to that participant and ensuring confidentiality. Data for all 
PACE-HD assessments will be entered in real-time into a custom-built database accessed via 
a secure web interface, after which it is automatically stored in a structured query language 
(SQL) database.  The database is engineered with in-built validations and warning messages 
that are rigorously tested for the use to ensure data quality. 
The C3T assessment will be completed via a native android application on a tablet. 
On test completion, data is transferred to the C3T SQL Live server and PACE-HD SQL live 
server simultaneously.  Data from Geneactiv monitors will be transferred to the co-ordinating 
centre where a pre-programmed algorithm will be applied to derive variables for analysis. 
Variables will be uploaded into the study database.   
Participants randomised to the intervention who choose to use Fitbit monitors will be 
assigned a unique username and password for their devices, and will be asked to sync their 
devices regularly (approximately every 5 days).  We will utilize a backend service platform, 
FitaBase, to aggregate participant Fitbit data, and at the completion of the study will export 
summary activity into the study database.  Additional clinical data will be obtained from 
Enroll-HD via a Specific Data Request detailing all the required variables from the extended 
battery data set. Enroll-HD data exports will be identified using the PACE-HD PID and the 
HDID (Enroll-HD participant identifier) will not be shared. All sites will maintain PID 
/HDID linking information. Data exports will be obtained at three time points: after 
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recruitment of 5 participants per site, at the close of recruitment when all baseline data has 
been completed, and at the completion of all follow up visits. No follow-up data will be 
collected from participants that have made a decision to withdraw from the study. 
 
[H2]Monitoring 
Data will be monitored remotely for completeness and validity throughout recruitment and 
follow-up via the study database. A log of all data queries and their resolution will be 
maintained. Safety events will be monitored by site staff at each interaction with participants. 
Trial progress in regard to screening, recruitment, retention, non-compliances and safety 
events will be monitored on a monthly basis at Trial Management Group (TMG) meetings 
and by the independent Trial Steering Committee (TSC) meeting every six months. This is a 
low risk study therefore no formal data monitoring committee will be convened. On-site 
monitoring will be performed by Enroll-HD data monitors for the dual purposes of verifying 
validity of consent and accuracy of the PID/HDID linking documentation. Participant 
allocation will be monitored for balance when approximately half the RCT participants have 
been randomized.   
 
[H2]Intervention Fidelity Monitoring 
Fidelity of the intervention will be measured using a combination of therapist self-report 
checklists (indicating whether the content of each of the sessions was consistent with that 
specified in the protocol and training manual) and therapist self-assessment completed using 
a purpose-developed rating scale.
25
 Intervention adherence will be assessed as part of the 
fidelity assessment in the process evaluation.   
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[H2]Analysis 
Descriptive statistics will summarize key demographic characteristics of all participants in 
the study (n = 120). Summary data for recruitment, retention and data completeness will be 
tabulated for the cohort and nested RCT. Adherence rates, safety and fidelity will be 
summarised for the RCT.  The primary feasibility outcome is the proportion of randomized 
participants that were followed-up at 12 months and will be presented with 95% confidence 
intervals along with all other feasibility outcomes. Secondary efficacy outcomes from the 
RCT will be explored and presented with effect sizes and 95% confidence intervals. 
Comparability of the observation only (n = 60) and RCT (n = 60) participants at 
baseline, will be explored using Enroll-HD data. Drop-out bias for the RCT will be assessed 
by comparing baseline data for those who were followed-up and those who were not at 12 
months.  No statistical tests will be performed on these data and only appropriate summary 
data tabulated. For the analysis of secondary outcomes, we will examine the differences in 
mean scores between arms at 12 months’ post-randomization with 95% confidence intervals. 
Linear models will be used for continuous outcomes where the distributional assumptions of 
the methods have been met and logistic regression for dichotomous outcomes with results 
presented as odds ratios and 95% confidence intervals. Covariates in the models will include 
individual participant characteristics used to balance the randomisation (age, gender, UHDRS 
total motor score) and the baseline score for each respective outcome. Analysis will be 
intention to treat and complete case.   
A mediation analysis will be performed on VO2 max recorded at 6 months to assess 
the role of physical activity and fitness on cognitive, motor and functional abilities. A 
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sensitivity analysis may be conducted using a mixed model to explore the extent of clustering 
in potential primary outcome variables by country if numbers permit.    
Progression criteria to proceed to further evaluation will be based on the following; over 60% 
drop-out from the RCT at 12 months will mean no progression, between 40 and 60 % drop-
out will mean that changes to the intervention and/or follow-up procedures will be required 
and less than 30% drop-out at 12 months will indicate that the intervention is suitable for 
further evaluation without modification.  
Summary data of weekly number of steps, average intensity and total intensity of 
exercise, hours of sleep, average heart rate and peak heart rate as gathered from FitBit 
activity monitors (intervention group only) will be explored for association with fitness (VO2 
max) at 6 and 12 months. We will also explore data on usual activity from self-reported 
physical activity assessments in relation to blinded Geneactiv activity data.  
Principal Component Analysis will be used to explore the validity of a composite 
outcome for HD. Recently it has been proposed that a composite outcome has greater validity 
in detecting disease modification in HD than through the selection of a single primary 
outcome measure.
26
 Where it is hypothesized that exercise interventions will impact of the 
triad of HD symptoms (motor, cognitive, and behavioral), a composite outcome would be 
more sensitive in detecting any meaningful disease modification, thus making this 
exploratory analysis of importance for interventions such as those being studied here. The 
composite will be based on motor and cognitive outcomes as suggested by Schobel et al
26
  
and will be compared between arms using confidence intervals. 
We will also use propensity score weights to create a pseudo-randomized trial of the 
intervention that compares the individuals in the intervention arm of the RCT to individuals 
in our Enroll-HD reference cohort. The propensity score weights will aim to make the two 
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groups comparable on a range of important characteristics that are associated with HD 
progression. The treatment effect estimates from the propensity score matched pseudo-
randomised groups will be compared with the treatment effect estimate from the randomised 
groups as a way to assess the utility of propensity score methodology relative to RCTs for 
obtaining treatment effect estimates for exercise interventions. 
[H2]Role of Funding Source 
This study has been funded by the Jacques and Gloria Gossweiler Foundation. The funder 
plays no role in the design or conduct of this study. 
[H1]ETHICS AND GOVERNANCE  
PACE-HD is sponsored by Cardiff University (resgov@cardiff.ac.uk) and retains overall 
responsibility for the trial, which is currently recruiting (opened February 2018).  Approval 
for the study has been obtained from the local Institutional Review Board (IRB) at each of the 
six sites (see supplementary materials for details of each site and their IRBs). 
The protocol was written according to the Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT) statement27 and this manuscript is based upon version 2.0 
(23 November 2017) of the study protocol. All protocol amendments will be communicated 
to participating sites and regulatory authorities by the co-ordinating centre. Study results will 
be published on ClinicalTrials.gov and in peer-reviewed literature
28
.  
 
[H1]DISCUSSION 
This trial incorporates several novel aspects that could transform how we approach the 
evaluation of long-term exercise interventions in participants with neurodegenerative 
diseases. HD is an excellent paradigm for other neurodegenerative disease and movement 
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disorder research. HD is a well- characterized, single gene disorder, as opposed to a cluster of 
symptomatically aligned disorders with differing aetiologies. This allows research 
methodologies and therapeutic interventions to be developed and evaluated, which may have 
high applicability to other related diseases. 
This study utilizes a TWiC design with the first longitudinal evaluation of a well-
defined exercise intervention in people with HD linking to a global cohort study 
supplemented with specific exercise-related outcome measures. PACE-HD employs a 
number of innovative methods for assessing life-style factors across a large, heterogeneous 
cohort. Incorporating routine data (from Enroll-HD) allows the use of a large, clinically 
relevant data set without the need for additional tests thereby reducing participant burden. 
This is particularly important in a rare disease population who are likely asked to be involved 
in multiple research studies. Wearable technologies are being employed to provide objective 
measures of physical activity. In combination with prospective activity and clinical data 
collection, this allows further validation of reliable and sensitive tools for assessing physical 
activity in real-world settings.  Propensity score matching allows for the suitability of pseudo-
randomised study designs to be assessed which may be of value in rare conditions where 
implementing randomised studies is difficult or unfeasible.  The innovative systematic 
approach proposed for this study will have wide-reaching impact that will advance the 
development of new therapeutic options. It will deliver a realistic, clinically applicable 
therapeutic option for people with HD that can be implemented in a variety of healthcare 
settings and can be used as a methodological model for evaluating similar lifestyle 
interventions in other disease populations.  
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Figure 1.  Schematic of participant flow through the study. 
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Figure 2.  Logic Model for the PACE-HD intervention.HD = Huntington’s disease; IPAQ = 
International Physical Activity Questionnaire; PA = Physical Activity; SF-12 = 12 item 
quality of life short form survey; UHDRS = Unified Huntington’s disease Rating score; 
UHDRS mMS = Unified Huntington’s disease Rating score (modified Motor Score)  
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ptj/advance-article-abstract/doi/10.1093/ptj/pzz075/5491339 by U
niversity of C
ardiff - Journal of Biochem
isty Trial user on 23 August 2019
  
 
Table. PACE-HD Specific Assessments
a 
Construct Measure Time Point 
(month) 
0 6 12 
All Sites 
Fitness Predicted VO2 Max  will be measured during stepwise incremental 
exercise test.
29
  The test is performed on a cycle ergometer with 
participants seated in a standardized position. Participants will 
attempt to maintain a cadence of 50 revolutions per minute (rpm), 
starting at 50 Watts and increasing by 25 Watts every 2 minutes until 
test termination. The test will be terminated when the participant 
reaches volitional exhaustion or cadence drops by 10 rpm. At the end 
of each minute, work-rate (Watts), rating of perceived exertion (Borg 
RPE scale), and heart rate will be recorded for analysis and 
conversion to predicted VO2 max score. 
  
(RCT 
only) 
 
Walking 
endurance 
The 6-minute walk test will be used as a measure of walking 
endurance. This test evaluates the distance walked over a 6 minute 
period, and has been validated for use in HD.
30
  
  
(RCT 
only) 
 
Participant-
reported 
clinical 
symptoms 
HD Pro-Triad,
31
 a quality of life measure specific to HD,  will be 
used to assess disease specific symptoms including cognitive decline, 
emotional/ behavioral disturbance, and motor dysfunction.  
   
Physical 
activity 
monitoring 
Brunel Lifestyle Physical Activity Questionnaire
32
 is a validated self-
report instrument that measures the planned and unplanned 
dimensions of lifestyle physical activity.  
   
Geneactiv accelerometers
18
 are research grade wrist-worn devices 
that continuously record physical and sedentary behaviours without 
feedback provided to the wearer.
33
 We are developing algorithms 
specific to HD to transform the accelerometer data into summary 
data specifying periods of physical activity, sedentary, and sleep 
behaviours.
34
 Participants will be given the monitors at baseline 
assessment and will be asked to return them after 7 days’ wear. Wear 
time will be 24 hours a day, except when showering. For validation 
of sleep time compared to sedentary time, participants will be asked 
to complete and return sleep diaries for the 7-day period of physical 
activity assessment.  
  
(RCT 
only) 
 
International Physical Activity Questionnaire (IPAQ, Short Form) 
measures the intensity and duration of physical activity undertaken in 
the last 7 days. It will be used to assess 7-day physical activity and to 
validate outputs of the physical activity monitors.
35
  
  
(RCT 
only) 
 
RCT Sites Only 
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Motor and dual 
task function 
The Clinch Token Transfer Test (C3T)
17
 is a novel dual-task 
assessment of bilateral, upper motor function that consists of 3-coin 
transfer tasks which increase in difficulty (baseline simple, baseline 
complex, and a dual task). The time taken to pick up and transfer the 
coins from dominant to non-dominant hand and place into a purpose 
developed box is recorded. The addition of cognitive load increases 
the task complexity. This has been shown to be highly sensitive 
across all stages of HD. 
   
Motor function Q-Motor was developed in TRACK-HD and TRACK-ON-HD where 
motor tasks are related to functionally relevant everyday tasks. All 
Q-Motor assessments are conducted using pre-calibrated and 
temperature controlled force transducers and 3D motion tracking
19
 
sensors with very high sensitivity and test-retest reliability across 
sessions and sites in a multicenter clinical trials involving 
participants with HD.
36,37
 
   
Cognitive 
function 
Q-Cog assessments deploy the technology used in the Q-Motor 
system to benefit from the high accuracy of the sensors in tasks with 
high cognitive load with the goal of providing a sensitive quantitative 
assessment of cognitive deficits in HD. Q-Cog assessments have 
high discriminative ability.
38
 Longitudinal performance has not yet 
been evaluated.  
   
Self-efficacy The Lorig Self Efficacy
39
 scale is a 6 item questionnaire validated for 
the assessment of self-efficacy in people with chronic conditions. In 
this study, it will be utilized to measure self-efficacy related to 
exercise (exercise sub-scale only) 
   
a
HD = Huntington disease; rct = randomized controlled trial; TRACK-HD = A 3 year 
prospective, observational study of people with HD and controls where imaging, cognitive 
and motor assessment data was collected. TRACK-ON-HD = extension of TRACK-HD to 
include pre-manifest HD participants  
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